Efficacy and Safety of Switching from Sitagliptin to Ipragliflozin in Obese Japanese Patients with Type 2 Diabetes Mellitus: A Single-Arm Multicenter Interventional Study.
Humans
Diabetes Mellitus, Type 2
/ complications
Sitagliptin Phosphate
/ adverse effects
Glycated Hemoglobin
East Asian People
Blood Glucose
Hypoglycemic Agents
/ adverse effects
Metformin
Dipeptidyl-Peptidase IV Inhibitors
/ therapeutic use
Sodium-Glucose Transporter 2 Inhibitors
/ adverse effects
Obesity
/ complications
Treatment Outcome
Drug Therapy, Combination
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
/ therapeutic use
Symporters
/ therapeutic use
Sodium
Journal
Clinical drug investigation
ISSN: 1179-1918
Titre abrégé: Clin Drug Investig
Pays: New Zealand
ID NLM: 9504817
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
accepted:
05
10
2023
medline:
11
12
2023
pubmed:
7
11
2023
entrez:
7
11
2023
Statut:
ppublish
Résumé
Dipeptidyl peptidase-4 inhibitors have limited efficacy in improving glycemic control for obese Japanese patients with type 2 diabetes mellitus. Sodium-glucose co-transporter 2 inhibitors are recommended for use in patients with type 2 diabetes with obesity. Nevertheless, there has been no previously published study on the effect of switching from dipeptidyl peptidase-4 inhibitors to sodium-glucose co-transporter 2 inhibitors on the systemic and organic effects in obese Japanese patients with type 2 diabetes. We evaluated the efficacy and safety of switching from sitagliptin to ipragliflozin for 24 weeks in obese Japanese patients with inadequately controlled type 2 diabetes. Fifty-one obese patients with type 2 diabetes (body mass index > 25 kg/m Fifty-one patients with an average HbA1c of 8.37 ± 0.48% and body mass index of 28.8 ± 3.8 kg/m Switching from sitagliptin to ipragliflozin did not alter HbA1c in obese patients with type 2 diabetes, while improving parameters related to organ homeostasis. These data provide novel information useful for selecting oral anti-diabetic agents for patients with type 2 diabetes with obesity, a risk factor for developing various complications of diabetes. Japan Registry of Clinical Trials identifier: jRCT#031190022.
Sections du résumé
BACKGROUND
BACKGROUND
Dipeptidyl peptidase-4 inhibitors have limited efficacy in improving glycemic control for obese Japanese patients with type 2 diabetes mellitus. Sodium-glucose co-transporter 2 inhibitors are recommended for use in patients with type 2 diabetes with obesity. Nevertheless, there has been no previously published study on the effect of switching from dipeptidyl peptidase-4 inhibitors to sodium-glucose co-transporter 2 inhibitors on the systemic and organic effects in obese Japanese patients with type 2 diabetes.
OBJECTIVES
OBJECTIVE
We evaluated the efficacy and safety of switching from sitagliptin to ipragliflozin for 24 weeks in obese Japanese patients with inadequately controlled type 2 diabetes.
METHODS
METHODS
Fifty-one obese patients with type 2 diabetes (body mass index > 25 kg/m
RESULTS
RESULTS
Fifty-one patients with an average HbA1c of 8.37 ± 0.48% and body mass index of 28.8 ± 3.8 kg/m
CONCLUSIONS
CONCLUSIONS
Switching from sitagliptin to ipragliflozin did not alter HbA1c in obese patients with type 2 diabetes, while improving parameters related to organ homeostasis. These data provide novel information useful for selecting oral anti-diabetic agents for patients with type 2 diabetes with obesity, a risk factor for developing various complications of diabetes.
CLINICAL TRIAL REGISTRATION
BACKGROUND
Japan Registry of Clinical Trials identifier: jRCT#031190022.
Identifiants
pubmed: 37934351
doi: 10.1007/s40261-023-01317-z
pii: 10.1007/s40261-023-01317-z
doi:
Substances chimiques
Sitagliptin Phosphate
TS63EW8X6F
ipragliflozin
3N2N8OOR7X
Glycated Hemoglobin
0
Blood Glucose
0
Hypoglycemic Agents
0
Metformin
9100L32L2N
Dipeptidyl-Peptidase IV Inhibitors
0
Sodium-Glucose Transporter 2 Inhibitors
0
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
EC 3.4.14.-
Symporters
0
Sodium
9NEZ333N27
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
927-937Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Marín-Peñalver JJ, Martín-Timón I, Sevillano-Collantes C, del Cañizo-Gómez FJ. Update on the treatment of type 2 diabetes mellitus. World J Diabetes. 2016;7:354–5. https://doi.org/10.4239/wjd.v7.i17.354 .
doi: 10.4239/wjd.v7.i17.354
pubmed: 27660695
pmcid: 5027002
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, on behalf of the American Diabetes Association, et al. Pharmacological approaches to glycemic treatment: standards of Medical Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl. 1):S140–57. https://doi.org/10.2337/dc23-S009 .
doi: 10.2337/dc23-S009
pubmed: 36507650
Bouchi R, Sugiyama T, Goto A, Imai K, Ihara-Sugiyama N, Ohsugi M, et al. Retrospective nationwide study on the trends in first-line antidiabetic medication for patients with type 2 diabetes in Japan. J Diabetes Investig. 2022;13:280–91. https://doi.org/10.4093/dmj.2011.35.3.300 .
doi: 10.4093/dmj.2011.35.3.300
pubmed: 34309213
Kim SA, Shim WH, Lee EH, Lee YM, Beom SH, Kim ES, et al. Predictive clinical parameters for the therapeutic efficacy of sitagliptin in Korean type 2 diabetes mellitus. Diabetes Metab J. 2011;35:159–65. https://doi.org/10.4093/dmj.2011.35.3.300 .
doi: 10.4093/dmj.2011.35.3.300
pubmed: 21738898
pmcid: 3122893
Sakai S, Kaku K, Seino Y, Inagaki N, Haneda M, Sasaki T, et al. Efficacy and safety of the SGLT2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus stratified according to baseline body mass index: pooled analysis of data from 52-week phase III trials. Clin Ther. 2016;38:843–62. https://doi.org/10.1016/j.clinthera.2016.01.017 .
doi: 10.1016/j.clinthera.2016.01.017
pubmed: 27021608
Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570–81. https://doi.org/10.1001/jama.287.19.2570 .
doi: 10.1001/jama.287.19.2570
pubmed: 12020339
Haller H. Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes: lessons from the FIGARO-DKD trial. Herz. 2022;47:401–9. https://doi.org/10.1007/s00059-022-05138-2 .
doi: 10.1007/s00059-022-05138-2
pubmed: 36094559
Cassano V, Crescibene D, Hribal ML, Pelaia C, Armentaro G, Magurno M, et al. Uric acid and vascular damage in essential hypertension: role of insulin resistance. Nutrients. 2020;12:2509. https://doi.org/10.3390/nu12092509 .
doi: 10.3390/nu12092509
pubmed: 32825165
pmcid: 7551393
Bolinder J, Ljunggren Ö, Kullberg J, Johansson L, Wilding J, Langkilde AM, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020–31. https://doi.org/10.1210/jc.2011-2260 .
doi: 10.1210/jc.2011-2260
pubmed: 22238392
Kawamoto R, Kohara K, Tabara Y, Miki T, Ohtsuka N, Kusunoki T, et al. An association between body mass index and estimated glomerular filtration rate. Hypertens Res. 2008;31:1559–64. https://doi.org/10.1291/hypres.31.1559 .
doi: 10.1291/hypres.31.1559
pubmed: 18971530
Yamamoto C, Miyoshi H, Ono K, Sugawara H, Kameda R, Ichiyama M, et al. Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy. Endocr J. 2016;63:589–96. https://doi.org/10.1507/endocrj.EJ15-0749 .
doi: 10.1507/endocrj.EJ15-0749
pubmed: 27052123
Sumida Y, Murotani K, Saito M, Tamasawa A, Osonoi Y, Yoneda M, et al. Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective, single-arm trial (lead trial). Hepatol Res. 2019;49:64–7. https://doi.org/10.1111/hepr.13236 .
doi: 10.1111/hepr.13236
pubmed: 30051943
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, EMPA-REG OUTCOME Investigators, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28. https://doi.org/10.1056/NEJMoa1504720 .
doi: 10.1056/NEJMoa1504720
pubmed: 26378978
Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, CVD-REAL Investigators and Study Group, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study. Circulation. 2017;136:249–59. https://doi.org/10.1161/CIRCULATIONAHA.117.029190 .
doi: 10.1161/CIRCULATIONAHA.117.029190
pubmed: 28522450
pmcid: 5515629
Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33. https://doi.org/10.1186/1471-230X-6-33 .
doi: 10.1186/1471-230X-6-33
pubmed: 17081293
pmcid: 1636651
Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ, Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:1104–12. https://doi.org/10.1016/j.cgh.2009.05.033 .
doi: 10.1016/j.cgh.2009.05.033
pubmed: 19523535
pmcid: 3079239
Kashiwagi A, Yoshida S, Nakamura I, Kazuta K, Ueyama E, Takahashi H, et al. Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: a subgroup analysis of five randomized clinical trials. J Diabetes Investig. 2016;7:544–54. https://doi.org/10.1111/jdi.12471 .
doi: 10.1111/jdi.12471
pubmed: 27181576
pmcid: 4931205
Kitazawa M, Katagiri T, Suzuki H, Matsunaga S, Yamada MH, Ikarashi T, et al. A52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study. Diabetes Obes Metab. 2021;23:811–21. https://doi.org/10.1111/dom.14288 .
doi: 10.1111/dom.14288
pubmed: 33416200
pmcid: 7898334
Son C, Makino H, Kasahara M, Tanaka T, Nishimura K, Taneda S, et al. Comparison of efficacy between dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor on metabolic risk factors in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2021;180: 109037. https://doi.org/10.1016/j.diabres.2021.109037 .
doi: 10.1016/j.diabres.2021.109037
pubmed: 34481910
Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36:2508–15. https://doi.org/10.2337/dc12-2491 .
doi: 10.2337/dc12-2491
pubmed: 23564919
pmcid: 3747923
Nakamura I, Maegawa H, Tobe K, Uno S. Safety and effectiveness of ipragliflozin for type 2 diabetes in Japan: 12-month interim results of the STELLA-LONG TERM Post-marketing surveillance study. Adv Ther. 2019;36:923–49. https://doi.org/10.1007/s12325-019-0895-1 .
doi: 10.1007/s12325-019-0895-1
pubmed: 30767112
pmcid: 6824450
Moon HU, Ha KH, Han SJ, Kim HJ, Kim DJ. The association of adiponectin and visceral fat with insulin resistance and β-cell dysfunction. J Korean Med Sci. 2019;34: e7. https://doi.org/10.3346/jkms.2019.34.e7 .
doi: 10.3346/jkms.2019.34.e7
pubmed: 30618514
Deacon CF. Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes. Front Endocrinol. 2019;10:80. https://doi.org/10.3389/fendo.2019.00080 .
doi: 10.3389/fendo.2019.00080
Panagiotakos DB, Pitsavos C, Yannakoulia M, Chrysohoou C, Stefanadis C. The implication of obesity on total antioxidant capacity in apparently healthy men and women: the ATTICA study. Nutr Metab Cardiovasc Dis. 2007;17:590–7. https://doi.org/10.1016/j.numecd.2006.05.007 .
doi: 10.1016/j.numecd.2006.05.007
pubmed: 16901682
Magkos F, Fraterrigo G, Yoshino J, Luecking C, Kirbach K, Kelly SC, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab. 2016;23:591–601. https://doi.org/10.1016/j.cmet.2016.02.005 .
doi: 10.1016/j.cmet.2016.02.005
pubmed: 26916363
pmcid: 4833627
Ohara M, Fukui T, Ouchi M, Watanabe K, Suzuki T, Yamamoto S, et al. Relationship between daily and day-to-day glycemic variability and increased oxidative stress in type 2 diabetes. Diabetes Res Clin Pract. 2016;122:62–70. https://doi.org/10.1016/j.diabres.2016.09.025 .
doi: 10.1016/j.diabres.2016.09.025
pubmed: 27810687
Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetes patients. J Clin Invest. 2014;124:499–508. https://doi.org/10.1172/JCI72227 .
doi: 10.1172/JCI72227
pubmed: 24463454
pmcid: 3904627
Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124:509–14. https://doi.org/10.1172/JCI70704 .
doi: 10.1172/JCI70704
pubmed: 24463448
pmcid: 3904617
Kuhre RE, Ghiasi SM, Adriaenssens AE, Wewer Albrechtsen NJ, Andersen DB, Aivazidis A, et al. No direct effect of SGLT2 activity on glucagon secretion. Diabetologia. 2019;62:1011–23. https://doi.org/10.1007/s00125-019-4849-6 .
doi: 10.1007/s00125-019-4849-6
pubmed: 30903205
pmcid: 7212061
Chae H, Augustin R, Gatineau E, Mayoux E, Bensellam M, Antoine N, et al. SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans. Mol Metab. 2020;42: 101071. https://doi.org/10.1016/j.molmet.2020.101071 .
doi: 10.1016/j.molmet.2020.101071
pubmed: 32896668
pmcid: 7554656
Morita Y, Ohno H, Kobuke K, Oki K, Yoneda M. Variation in plasma glucagon levels according to obesity status in Japanese Americans with normal glucose tolerance. Endocr J. 2021;68:95–102. https://doi.org/10.1507/endocrj.EJ20-0366 .
doi: 10.1507/endocrj.EJ20-0366
pubmed: 32908087
Manell H, Staaf J, Manukyan L, Kristinsson H, Cen J, Stenlid R, Ciba I, et al. Altered plasma levels of glucagon, GLP-1 and glicentin during OGTT in adolescents with obesity and type 2 diabetes. J Clin Endocrinol Metab. 2016;101:1181–9. https://doi.org/10.1210/jc.2015-3885 .
doi: 10.1210/jc.2015-3885
pubmed: 26745255
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, CREDENCE Trial Investigators, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–306. https://doi.org/10.1056/NEJMoa1811744 .
doi: 10.1056/NEJMoa1811744
pubmed: 30990260
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, DAPA-CKD Trial Committees and Investigators, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436–46. https://doi.org/10.1056/NEJMoa2024816 .
doi: 10.1056/NEJMoa2024816
pubmed: 32970396
Sasaki T, Sugawara M, Fukuda M. Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT Study. J Diabetes Investig. 2019;10:108–17. https://doi.org/10.1111/jdi.12851 .
doi: 10.1111/jdi.12851
pubmed: 29660782
Yun HR, Kim H, Park JT, Chang TI, Yoo TH, Kang SW, Korean Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD), et al. Investigators Obesity, metabolic abnormality, and progression of CKD. Am J Kidney Dis. 2018;72:400–10. https://doi.org/10.1053/j.ajkd.2018.02.362 .
doi: 10.1053/j.ajkd.2018.02.362
pubmed: 29728317
Straznicky NE, Grima MT, Lambert EA, Eikelis N, Dawood T, Lambert GW, et al. Exercise augments weight loss induced improvement in renal function in obese metabolic syndrome individuals. J Hypertens. 2011;29:553–64. https://doi.org/10.1097/HJH.0b013e3283418875 .
doi: 10.1097/HJH.0b013e3283418875
pubmed: 21119532
Chagnac A, Weinstein T, Herman M, Hirsh J, Gafter U, Ori Y. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephorol. 2003;14:1480–6. https://doi.org/10.1097/01.asn.0000068462.38661.89 .
doi: 10.1097/01.asn.0000068462.38661.89
Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kid Int. 2004;65:1870–6. https://doi.org/10.1111/j.1523-1755.2004.00582.x .
doi: 10.1111/j.1523-1755.2004.00582.x
Morales E, Valero MA, León M, Hernández E, Praga M. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis. 2003;41:319–27. https://doi.org/10.1053/ajkd.2003.50039 .
doi: 10.1053/ajkd.2003.50039
pubmed: 12552492
Kitada M, Hirano T, Koya D. Signifcance of SGLT2 inhibitors: Lessons from renal clinical outcomes in patients with type 2 diabetes and basic researches. Diabetol Int. 2020;11:245–51. https://doi.org/10.1007/s13340-020-00444-8 .
doi: 10.1007/s13340-020-00444-8
pubmed: 32802705
pmcid: 7387389
Tomita I, Kume S, Sugahara S, Osawa N, Yamahara K, Yasuda-Yamahara M, et al. SGLT2 inhibition mediates protection from diabetes kidney disease by promoting ketone body-induced mTORC1 inhibition. Cell Metab. 2020;32:404–19. https://doi.org/10.1016/j.cmet.2020.06.020 .
doi: 10.1016/j.cmet.2020.06.020
pubmed: 32726607
Koike M, Saito H, Kohno G, Takubo M, Watanabe K, Ishihara H. Effects of GLP-1RA and SGLT2i, alone or in combination, on mouse models of type 2 diabetes representing different disease stages. Int J Mol Sci. 2021;22:11463. https://doi.org/10.3390/ijms222111463 .
doi: 10.3390/ijms222111463
pubmed: 34768897
pmcid: 8583813